- Home
- COLL vs CRF Comparison
COLL vs CRF Comparison
Compare COLL & CRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- CRF
- Stock Information
- Founded
- COLL 2002
- CRF 1973
- Country
- COLL United States
- CRF United States
- Employees
- COLL N/A
- CRF N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- CRF Finance/Investors Services
- Sector
- COLL Health Care
- CRF Finance
- Exchange
- COLL Nasdaq
- CRF Nasdaq
- Market Cap
- COLL 1.1B
- CRF 1.2B
- IPO Year
- COLL 2015
- CRF N/A
- Fundamental
- Price
- COLL $35.95
- CRF $8.11
- Analyst Decision
- COLL Strong Buy
- CRF
- Analyst Count
- COLL 4
- CRF 0
- Target Price
- COLL $44.25
- CRF N/A
- AVG Volume (30 Days)
- COLL 311.7K
- CRF 1.1M
- Earning Date
- COLL 11-06-2025
- CRF 01-01-0001
- Dividend Yield
- COLL N/A
- CRF 18.10%
- EPS Growth
- COLL N/A
- CRF N/A
- EPS
- COLL 1.06
- CRF 1.40
- Revenue
- COLL $707,007,000.00
- CRF $11,461,786.00
- Revenue This Year
- COLL $21.29
- CRF N/A
- Revenue Next Year
- COLL $3.36
- CRF N/A
- P/E Ratio
- COLL $34.09
- CRF $5.38
- Revenue Growth
- COLL 22.61
- CRF 6.53
- 52 Week Low
- COLL $23.23
- CRF $5.70
- 52 Week High
- COLL $39.95
- CRF $9.56
- Technical
- Relative Strength Index (RSI)
- COLL 59.69
- CRF 58.19
- Support Level
- COLL $33.89
- CRF $8.01
- Resistance Level
- COLL $35.90
- CRF $8.05
- Average True Range (ATR)
- COLL 1.05
- CRF 0.09
- MACD
- COLL 0.27
- CRF 0.01
- Stochastic Oscillator
- COLL 89.72
- CRF 96.04
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About CRF Cornerstone Total Return Fund Inc. (The)
Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology; Health Care; Financials; Communication Services; Consumer Discretionary; Industrials; Exchange-Traded Funds; Utilities; Energy; Real Estate and others.